The Market Access Podcast: Will AI and Living Reviews Define the Next Era of Health Care Market Access?
Oncoscope-AI Founder & CEO Anna Forsythe was recently on the Market Access Podcast with Dr. Stefan Walzer to discuss how Living Systematic Literature Reviews (Living SLRs) are redefining evidence generation in oncology and beyond – highlighting the power of real-time updates, advanced automation, and the essential role of human insight. Traditional SLRs are static snapshots, while Living SLRs are real-time, dynamic, and AI-powered—delivering continuously updated insights crucial for life-or-death decisions and payer evaluations. Join this discussion as they explore the myth of AI chatbots as true decision support tools, the need for actionable data over summaries, and the future of evidence synthesis, clinical decision-making, and smarter market access. Listen on Spotify: Listen on YouTube: Listen on PocketCasts:
The Healthy Enterprise Podcast: AI’s Role in Modern Oncology – A New Era of Evidence-Based Cancer Care
Our very own Founder & CEO Anna Forsythe was recently on The Healthy Enterprise podcast to talk about Oncoscope-AI and how our practice-changing platform delivers real-time treatment insights, clinical guidelines, and research to support oncologists in an ever-evolving cancer landscape. Watch on YouTube: Listen on Spotify: Listen on Pocket Casts: From The Healthy Enterprise Podcast: In this episode of The Healthy Enterprise, Anna Forsythe, founder and CEO of Oncoscope-AI, shares her journey from manually processing oncology data to creating an AI-powered platform that delivers real-time treatment insights, clinical guidelines, and research to support oncologists in an ever-evolving cancer landscape. She discusses the importance of reliable evidence in decision-making, the positive response from physicians using the free platform, and the role of systematic data reviews in building trust and efficiency. Beyond the technology, Anna reflects on her entrepreneurial path, the challenges and opportunities of leading in healthcare, and the importance of cultivating talent, mission-driven culture, and visionary leadership. The conversation concludes with her insights on business models, community impact, and the future of AI in advancing cancer care. Chapters: 00:00 Introduction to Oncoscope-AI and Anna Forsythe03:04 The Need for Real-Time Oncology Data05:59 Transitioning from Manual to Automated Data Processing09:11 The Role of AI in Oncology12:13 Feedback and Response from Healthcare Professionals14:45 Data Sources and Systematic Reviews in Oncology18:02 Future Developments and Expanding Services21:53 AI in Research: Balancing Trust and Efficiency25:52 Business Model and Revenue Streams29:44 Personal Journey and Altruism in Business32:56 Challenges and Opportunities in Healthcare35:34 Leadership and Team Dynamics39:29 Visionary Leadership and Future Aspirations Guest Information: Takeaways: Keywords: Oncology, AI, healthcare, data processing, clinical guidelines, cancer treatment, healthcare technology, real-time data, systematic reviews, healthcare professionals, AI, healthcare, business model, cancer treatment, research, leadership, altruism, revenue streams, technology, innovation Enjoy this clip from the episode:
Founder Spotlight: Anna Forsythe, PharmD — Bringing Clarity to the Chaotic and Rapid Data Influx in Oncology with Oncoscope AI
As seen in Oncologist Daily, ASCO 2025 Edition The pace of progress in oncology is both exhilarating and overwhelming. New clinical trials, biomarkers, FDA approvals, and updated guidelines appear almost daily, creating a deluge of information that even the most diligent oncologists struggle to absorb. For Anna Forsythe, who had lost two good friends to cancer — and who is trying to help a third with a difficult diagnosis — this was more than just a challenge. It was a call to action. As the founder of Oncoscope AI, Anna has set out to build what she calls “a GPS for oncology.” Much like a car navigation system that recalculates routes in real time based on constantly changing traffic patterns, Oncoscope AI continuously updates to reflect the latest evidence — synthesizing and collating research data, treatment guidelines and regulatory approvals into a single, streamlined view designed for oncologists to use in real time at the point of care. “Oncoscope doesn’t replace the physician’s judgment,” Forsythe explains. “It augments it — giving clinicians a clear, current, and unbiased and easy to use view of what’s changing in real time, so they can spend less time digging through papers and more time with their patients.” This balance of innovation and practicality reflects Anna’s own background. A clinically trained Doctor of Pharmacy, she holds a Master’s Degree in Health Economics and Policy from the University of Birmingham (UK) and an MBA from Columbia University. Her career spans both the clinical and strategic sides of the pharmaceutical industry — with leadership in both oncology and non-oncology roles roles in global value and access at Eisai Co., and earlier positions at Novartis and Bayer in clinical research and health economics. She’s no stranger to entrepreneurship either. Anna previously co-founded Purple Squirrel Economics, a health economics consultancy that was acquired by Cytel, the Cambridge, Massachusetts-based statistical software developer and contract research organization, in 2020. Her work has appeared in leading journals and conference podiums alike, including a top-ranked JAMA Pediatrics article, which placed in the top 5 percent of all JAMA research outputs worldwide. But it’s Oncoscope that brings her experiences full circle — combining clinical insight, economic acumen, and a passion for scalable solutions that work in real-world oncology settings. As thousands of oncologists gather at ASCO 2025 to digest the latest data and translate it into better care, Oncoscope AI offers a timely reminder that innovation doesn’t have to be overwhelming — if it’s built from the ground up with the physician in mind. “We’re not a technology in search of an application — and we’re not at all suggesting that oncologists change how they practice,” says Forsythe. “They are the experts. We are merely helping them by building a tool that fits seamlessly into their reality — one that helps them keep up with the latest information, and communicate the most up-to-date strategies clearly with patients. The goal is to help them stay focused on what matters most: delivering the best possible care.” With Oncoscope AI, Anna Forsythe is leading a new kind of precision oncology — one where evidence and empathy meet at the bedside, powered by smart, real-time technology. Anna Forsythe is the Founder and President of Oncoscope-AI, the first platform to bring together real-time oncology treatment data, clinical guidelines, research publications, and regulatory approvals — all in one place, just like Expedia for cancer care. Available free to oncology professionals worldwide, Oncoscope-AI is redefining how cancer care information is accessed and applied. A clinically trained Doctor of Pharmacy (PharmD), Anna also holds a Master’s in Health Economics and Policy from the University of Birmingham (UK) and an MBA from Columbia University. She previously co-founded Purple Squirrel Economics (acquired by Cytel in 2020) and led Global Value and Access at Eisai Pharmaceuticals, following earlier roles at Novartis and Bayer in clinical research and health economics.